About this trial
The aim of this observational study is to investigate the impact of body composition on the absorption, distribution, and metabolism of drugs. The primary question it seeks to answer is: Does body composition affect the absorption, distribution, and metabolism of drugs? By combining pharmacokinetic parameters and adverse drug reactions, the study will analyze differences in the metabolism of drugs under various body composition conditions.
During the Phase I clinical trial, under the guidance of the researchers, subjects will use the non-invasive InBody S10 body composition analyzer to obtain body composition data, including but not limited to inorganic salts, muscle mass, lean body mass, body weight, and body fat percentage.
Eligibility criteria
Qualifiers
Participants who have been successfully enrolled in the bioequivalence trials of Progesterone Sustained-release vaginal gel;
Have signed the informed consent form, have a full understanding of the content, process, and risks of this study, and can communicate well with the researchers.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed